Planet 13 Holdings (PLNH) Total Non-Current Liabilities (2020 - 2026)
Planet 13 Holdings (PLNH) posted quarterly Total Non-Current Liabilities of $101.9 million for Q1 2026, up 38.23% year-over-year from $73.7 million in Q1 2025, and up 49.65% quarter-over-quarter from $68.1 million in Q4 2025.
Planet 13 Holdings (PLNH) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has reported Total Non-Current Liabilities for 7 consecutive years, with $101.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 38.23% year-over-year to $101.9 million; the TTM figure through Mar 2026 stood at $101.9 million (up 38.23% YoY), while the FY2025 annual figure was $68.1 million, down 8.82% from the prior year.
- Total Non-Current Liabilities advanced to $101.9 million in Q1 2026 per PLNH's latest filing, from $68.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $102.6 million in Q3 2025 and bottomed at $35.5 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $61.3 million across 5 years, with a median of $45.6 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 671.38% — and 2025, when it declined 9.71%.
- Planet 13 Holdings' Total Non-Current Liabilities stood at $42.7 million in 2022, then climbed by 3.19% to $44.1 million in 2023, then jumped by 69.36% to $74.7 million in 2024, then slipped by 8.82% to $68.1 million in 2025, then jumped by 49.65% to $101.9 million in 2026.
- Business Quant data shows PLNH's Total Non-Current Liabilities at $101.9 million in Q1 2026, $68.1 million in Q4 2025, and $102.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Planet 13 Holdings | 52.64 Mn | 36.16 Mn | 12.32 Mn | 65.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.37 Mn |
| Mar 31, 2026 | 101.92 Mn |
| Dec 31, 2025 | 68.11 Mn |
| Sep 30, 2025 | 102.65 Mn |
| Jun 30, 2025 | 76.15 Mn |
| Mar 31, 2025 | 73.74 Mn |
| Dec 31, 2024 | 74.70 Mn |
| Sep 30, 2024 | 92.25 Mn |
| Jun 30, 2024 | 84.34 Mn |
| Mar 31, 2024 | 45.62 Mn |
| Dec 31, 2023 | 44.11 Mn |
| Sep 30, 2023 | 41.52 Mn |
| Jun 30, 2023 | 40.44 Mn |
| Mar 31, 2023 | 40.95 Mn |
| Dec 31, 2022 | 42.74 Mn |
| Sep 30, 2022 | 35.88 Mn |
| Jun 30, 2022 | 35.50 Mn |
| Mar 31, 2022 | 41.17 Mn |
| Dec 31, 2021 | 43.07 Mn |
| Mar 31, 2021 | -7.21 Mn |